NEW YORK (GenomeWeb) – Signal Genetics said before the opening of the market that its first quarter revenues increased 27 percent year over year.

For the three months ended March 31, the Carlsbad, California-based molecular diagnostics firm reported revenue of $818,000, up from $645,000 a year ago, attributable to a record number of tests billed for clinical patients, the firm said in a statement.

The number of tests billed for increased 93 percent year over year, due to increased commercial presence, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.